Cure My Disease

Don't miss your cure!

 Log in / Sign up

Sugar substitutes may trigger blood clotting, study warns

NCT ID NCT04731363

Knowledge-focused Sponsor: The Cleveland Clinic Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 14, 2026 · Updated 2 times

Summary

This study looks at whether drinking a beverage with artificial sweeteners (erythritol or xylitol) changes how blood platelets clump together, which could affect heart attack or stroke risk. Researchers will measure platelet activity and blood levels of these sweeteners in 50 healthy adults before and after consumption. The goal is to understand if these common sugar substitutes might increase cardiovascular risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

50 people

The number who actually took part.

Started

Mar 2021

Finished

Apr 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Cohort 1 Inclusion Criteria: * Age 18 years or above. * Willing and able to sign the consent form. Cohort 1 Exclusion Criteria: * Use of anti-platelet medications within 14 days of study enrollment. * Active infection or received antibiotics within 1 month of study enrollment. * Use of over-the-counter probiotic within 1 month of study enrollment. * Diabetes mellitus * Ulcerative colitis, Crohn's disease, or other chronic gastrointestinal disorder. * Past history of bariatric procedures or surgeries (e.g. gastric banding or bypass). * Pregnancy. * Significant chronic illness. Cohort 2 Inclusion Criteria: * Men and women age 18 years or above. * Able to provide informed consent and comply with study protocol. * Diabetes Mellitus Type II Cohort 2 Exclusion Criteria: * Use of anti-platelet medications within 14 days of study enrollment. * Active infection or received antibiotics within 1 month of study enrollment. * Use of over-the-counter probiotic within 1 month of study enrollment. * Ulcerative colitis, Crohn's disease, or other chronic gastrointestinal disorder. * Past history of bariatric procedures or surgeries (e.g. gastric banding or bypass). * Pregnancy. * Any condition that, in the judgment of the Investigator, would place a subject at undue risk by being enrolled in the trial or cause inability to comply with the trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiovascular risk factor are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiovascular risk factor

Contacts and locations

Locations

  • Cleveland Clinic

    Cleveland, Ohio, 44195, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.